Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

IRVINE, Calif., March 26 /PRNewswire-FirstCall/ -- NuRx Pharmaceutical Inc.'s (OTC Bulletin Board: NURX) next-generation rexinoid agonist, NRX4204, significantly reduced the number and size of lung tumors and lowered the total tumor volume in mouse models compared to the control group, according to a paper published in Clinical Cancer Research (2007; Vol. 13, Issue 20: 6237-6243).

In addition, the paper showed that NRX4204 caused marked tumor regression in all of the mammary tumors when used therapeutically. Rexinoids regulate cell proliferation, differentiation, and apoptosis pathways.

Entitled "A New Rexinoid, NRX4204, Prevents Carcinogenesis in Both Lung and Mammary Gland," the paper is based on a study that first evaluated the anti-inflammatory effects of NRX4204 and its growth-inhibitory properties in vitro and then measured the compound's ability to prevent and/or treat experimental lung and estrogen receptor (ER)-negative breast cancer in vivo.

"This study demonstrates that NRX4204 is exceptionally potent and not only reduces the number and size of adenocarcinomas in the lung, but it also prevents the development of mammary tumors and induces striking tumor regression in established mammary tumors," said Michael Sporn, Ph.D., professor of pharmacology and toxicology and of medicine at Dartmouth Medical School and the study's principal investigator. "For the first time, NRX4204 also showed effects as an anti-inflammatory agent in cell culture models that are highly relevant for human inflammatory diseases."

Harin Padma-Nathan, M.D., President and CEO of NuRx Pharmaceuticals said: "In this study, NRX4204 exhibited dramatic effects in the prevention of the development of lung cancer and in the prevention and treatment of breast cancer in spontaneous models. We have initiated a Phase I clinical trial and intend to pursue the development of this compound as a treatment for both lung and breast cancer. There are no rexinoid treatm
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., LUND, Sweden, December 2 Der...atology and wound healing company "Pergamum" -,tod...ng results from a,clinical Phase I/IIa study. Derm...e (AMP) treatment for atopic dermatitis. Atopic de...ere dry skin and the skin,s weakened barrier,funct...
(Date:12/2/2009)...HAIFA, Isreal, December 2 /PRNewswire-FirstCall/ -...a leading developer of advanced,cardiovascular sur...s Board,of Directors approved a one-for-three forw...payable to Cardio Vascular Medical Device sharehol...course the estimated date the stock,split will be ...
(Date:12/2/2009)...M, Ala., Dec. 2 Adults are more ... cancer. For adults 65 and over, the odds of losin...an developing prostate cancer are one in six and o... nine. Vision loss threatens the overall health o... depression and inability to complete daily tasks....
Breaking Medicine Technology:Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4Cardio Vascular Medical Device Announces Forward Stock Split 2Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4 2009 14629 1Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4 2009 14629 2Voler Systems Reports 50 25 Growth 14626 1Voler Systems Reports 50 25 Growth 14626 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3
...tients with fibromyalgia treated with 60mg or 120m...ter reduction in pain severity beginning,one week ...o (sugar pill),as measured by the Brief Pain Inven...cluded patients with and without depression, also ...oxetine than in those taking,placebo in scores on ...
...lated for IND Filing By ... Pharmaceuticals, Inc., a,clinical-stage biopharma...ping novel RNA interference-based therapeutics, an...p with the State University of New York at,Buffalo...any,s primary site,for the pre-clinical studies of...
Other Medicine Technology:New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression 2New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression 3New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression 4New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression 5Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:12/2/2009)... , KNOXVILLE, Tenn., Dec. 2 Te...ce in Southwest Florida with the acquisition of Na...N). Since January 2002, EPN has held an exclusive...emergency facilities at the Downtown Naples Hospit...e Clinic. EPN also provides the staffing for two s...
(Date:12/2/2009)...ECHO 2009 is the official congress of the European...ed branch of the European Society of Cardiology, w... will be presented. , New case reports will be ... evidence highlighting the role of this new techno...ging techniques, it is likely that non-invasive im...
(Date:12/2/2009)... Revolutionary new cell phones ...om users will be available in early 2010 from Aeri...(PRWEB) December 2, 2009 -- Revolutionary new cell... away from users will be available in early 2010 f...ecently honored with a Green Technology Award in w...
(Date:12/2/2009)... , CHICAGO, Dec. 2 T...ion,s Board of Directors today announced Alan F. D...he 55,000-member health information management (HI...tion experience includes academia, systems managem... and not-for-profit executive leadership. He is s...
(Date:12/2/2009)... , Ad in Today,s Washington Post Highli...-USNewswire/ -- If the Catholic bishops have th...measures we take for granted may be under threat. ...bear on the debate over healthcare reform has been...ton Post warns of the likely impact if that press...
Breaking Medicine News(10 mins):Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Media alert: EUROECHO 2009 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
...ing touted as a new age elixir. So another researc..., PhD, Boyd Professor// and Director of the Neuro...s Centre in New Orleans, in a paper reports on the...ated macular degeneration, the leading cause of lo...
...icago in collaboration with their colleagues from ... an enzyme in the virus that causes SARS//, severe...have detailed these findings in the March 27 issue...nsional structure of this enzyme -- known as papai...
...the effect of tiny nanoparticles on the health of ...ion// from traffic exhaust and are also used in ma..., cosmetics and clothes. The scientists will asses...properties according to their composition, which e...
...lth CenterSM conducted a survey on feminine hygien...oday's American women are taking active roles in t...two thirds of women aged 18 and older (63 percent)... still a level of embarrassment in discussing wome...
...rmed as new rules are being implemented that will...k// in hospitals of the National Health Service (...ors from the Indian subcontinent who could sudden...n Union (EU) doctors. So far doctors from o...
...cious, but dying from cancer can certainly be avoi...en, it would obviously warrant lifestyle changes; ...ious food habits, regular exercise, and screenings...nd program director of risk-factor surveillance fo...
Other Medicine News:Health News:Women aware of “feminine health” : their attitud 2Health News:Work Permit Required For Indian Doctors in Britain 2Health News:Work Permit Required For Indian Doctors in Britain 3Health News:Did You Know That 50% Of Deaths Due To Cancer, Can be Prevented? 2
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: